A burgeoning corpus of research underscores that provoking ferroptosis—by amplifying intracellular Fe2+ concentrations, escalating levels of ROS, curtailing the availability of the antioxidant glutathione (GSH), or rendering GPX4 inactive—can significantly influence the therapeutic landscape of CRC.18, 19. Here, GPX4 is linked to colorectal carcinoma.